Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist

Kim R Tsuchimoto

Director at Monopar Therapeutics (MNPR)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $911K

Reported trades

Filed Stock Type Shares Price Value Since
Aug 28SEC MNPRMonopar Therapeutics Sell Plan 4853,605 held (−12%) $108.83 $53K -27.4%
Aug 28SEC MNPRMonopar Therapeutics Sell Plan 6152,990 held (−17%) $109.56 $67K -27.9%
Aug 28SEC MNPRMonopar Therapeutics Sell Plan 7002,290 held (−23%) $110.65 $77K -28.6%
Aug 28SEC MNPRMonopar Therapeutics Sell Plan 1,0981,192 held (−48%) $111.84 $123K -29.4%
Aug 28SEC MNPRMonopar Therapeutics Sell Plan 602590 held (−51%) $112.93 $68K -30.1%
Aug 28SEC MNPRMonopar Therapeutics Sell Plan 590 $113.84 $67K -30.6%
Aug 27SEC MNPRMonopar Therapeutics Sell Plan 48511,001 held (−4%) $108.83 $53K -27.4%
Aug 27SEC MNPRMonopar Therapeutics Sell Plan 61510,386 held (−6%) $109.56 $67K -27.9%
Aug 27SEC MNPRMonopar Therapeutics Sell Plan 7009,686 held (−7%) $110.65 $77K -28.6%
Aug 27SEC MNPRMonopar Therapeutics Sell Plan 1,0988,588 held (−11%) $111.84 $123K -29.4%
Aug 27SEC MNPRMonopar Therapeutics Sell Plan 6027,986 held (−7%) $112.93 $68K -30.1%
Aug 27SEC MNPRMonopar Therapeutics Sell Plan 5907,396 held (−7%) $113.84 $67K -30.6%
  • Sell

    Director Kim R Tsuchimoto sold $53K of MNPR at $108.83 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kim R Tsuchimoto sold $67K of MNPR at $109.56 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kim R Tsuchimoto sold $77K of MNPR at $110.65 — pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kim R Tsuchimoto sold $123K of MNPR at $111.84 — cuts the stake by 48%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kim R Tsuchimoto sold $68K of MNPR at $112.93 — cuts the stake by 51%; pre-scheduled 10b5-1 plan sale.

  • Sell

    Director Kim R Tsuchimoto sold $67K of MNPR at $113.84 — pre-scheduled 10b5-1 plan sale.